
Pharmacally
Schizophrenia
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Schizophrenia
Clinical TrialsTortugas Reports Positive Phase 2b Results for Obuprazine in SchizophreniaTortugas Neuroscience reported that obuprazine met the Phase 2b primary endpoint in schizophrenia, with all three dose groups significantly improving PANSS scores versus placebo.Fact-Checked
Medical DevicesClick’s Motivista Receives FDA Clearance for Negative Symptoms of SchizophreniaClick Therapeutics’ Motivista (CT-155) has received FDA 510(k) clearance as an adjunctive prescription digital therapeutic for negative symptoms of schizophrenia in adults with clinically stable positive symptoms.Fact-Checked
Clinical TrialsTeva’s UZEDY Shows Real-World Benefits in SchizophreniaTeva presented new real-world data for UZEDY (risperidone) showing greater treatment continuity and lower emergency care use in schizophrenia, alongside lower treatment failure after switching from oral antipsychotics…Fact-Checked
Clinical TrialsTEV-‘749 Shows Durable Results in Phase 3 Schizophrenia TrialTeva’s investigational once-monthly subcutaneous olanzapine LAI TEV-‘749 showed durable stabilization and low relapse in a Phase 3 SOLARIS analysis, while switching analyses supported predictable olanzapine exposure after transition…Fact-Checked
Health TidingsEli Lilly Joins $30 Million Series A to Advance Leal’s Schizophrenia and ALS ProgramsLeal Therapeutics has secured $30 million in a second Series A financing to advance LTX-001 through a Phase 1b/2a trial in schizophrenia and expand LTX-002 development in ALS…Fact-Checked
Health TidingsMapLight Reports Positive Phase 2 Results for ML-007C-MA in SchizophreniaMapLight Therapeutics reported positive Phase 2 ZEPHYR results for ML-007C-MA, an investigational oral combination of betovumeline and fesoterodine, in adults with acute schizophrenia.Fact-Checked
Health TidingsEMA Accepts TEV-‘749 Application for Adults With SchizophreniaTeva and Medincell’s investigational long‑acting olanzapine, TEV‑‘749, has advanced after EMA accepted its Marketing Authorization Application.Fact-Checked
Mergers & AcquisitionsBoehringer, Click Move CT-155 to Frontline in SchizophreniaClick Therapeutics will lead commercialization of CT-155 after Boehringer Ingelheim transfers full product responsibility and invests $50 million, supported by Phase III CONVOKE data showing improvement in schizophrenia…Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.